X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Low-Dose COVID Vaccine From Moderna Safe For Kids Under Six

Content Team by Content Team
25th March 2022
in News
Moderna To introduce The Fusion Of COVID-19 And Flu Booster

Moderna has published the mid-term findings of its COVID-19 vaccination for children under the age of six. Two 25-microgram doses of the COVID-19 vaccine for kids aged 6 months to 5 years old generated an immune response comparable to two 100-microgram doses for adults aged 18 to 25, indicating that the advantage imparted on young adults is also conferred on young children, according to the company. The vaccination is administered to children in two doses, 28 days apart.

According to a corporate news release issued, the data showed a significant neutralising immune reaction and a positive safety profile. The pharma giant has confirmed that it will pursue the US FDA in few weeks to approve the vaccine’s use in this younger age range based on the evidence.

Moderna CEO Stéphane Bancel said that given the need for a vaccination against COVID-19 in newborns and young children, they are collaborating with the US FDA and regulators around the world to submit these findings as quickly as feasible. These current findings appear to be highly favourable for parents with kids under the age of six.

The vaccine was insufficient to prevent COVID-19 infections caused by the Omicron strain, which was common in the US at the time of the study. The effectiveness was 43.7 percent for children aged 6 months to one year.

The performance was 37.5 percent for children aged 2 to 5. The less efficient outcome was nonetheless statistically significant, according to Moderna, and comparable to how vaccinated individuals had fared with the Omicron version.

Moderna said it is planning to assess the possibility of a booster shot for all kids aged 6 months and up, which would target both the original strain and the Omicron type of the virus. The figures are based on a sample of 6,900 kids aged 6 months to 5 years old. The majority of side effects are mild to moderate, and they become more common after the second dose. According to Moderna, no deaths or instances of myocarditis or pericarditis have been documented. It is well to be noted that the infection of the heart muscle is myocarditis, while the infection of the heart membrane is pericarditis. The company also stated that it has started the process of applying to the FDA for urgent use authorisation of its COVID-19 vaccine for children aged 6 to 11. Two doses of a bigger 50-microgram form of the vaccine would be given to children of that age. Moderna also stated that it provided further follow-up statistics on its vaccination for youngsters aged 12 to 17 to the FDA. Two doses of a bigger 100-microgram form of the vaccine would be given to children in that bracket.

The FDA delayed a meeting of its vaccine advisors last month to discuss Pfizer and BioNTech’s vaccine for children under the age of five and asked for further evidence on third doses. The companies have stated that the data will be available in early April.

Previous Post

Pharmaceutical Branded Market Keeps Making Headways In China

Next Post

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In